This site is intended for healthcare professionals
News

BioDelivery Sciences International completes acquisition of Elyxyb for acute migraine treatment in the U.S. and Canada.

Read time: 1 mins
Last updated:10th Sep 2021
Published:10th Sep 2021
BioDelivery Sciences International, Inc. a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced that it has completed the acquisition of U.S. and Canadian rights to Elyxyb (celecoxib oral solution) from Dr. Reddy’s Laboratories Limited.
Condition: Migraine/Headache
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest